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Abstract
Background: To evaluate the impact of the 2002 Women's Health Initiative (WHI) study results
on the prescription of menopausal hormone therapy (MHT) to treat menopause-related symptoms
in Taiwan.
Methods: This retrospective study participant data collected from women interviewed in 2001
Taiwan's National Health Interview Survey (NHIS) and the National Health Insurance (NHI)
outpatient claims for women being treated for menopause-related symptoms. We compared
prescriptions made for MHI to women seeking outpatient treatment for menopause-related
symptoms before and after the publication of the 2002 WHI to study its effect of prescription
behavior in Taiwan. There was one dichotomous outcome variable, which was whether MHT was
prescribed or not in an outpatient visit to treat menopause-related symptoms.
Results: Our study included 504 women 45 years old or above whose outpatient visits for
menopause-related symptoms were covered by National Health Insurance in 2002. In total, these
504 women made 2549 outpatient visits to be treated for these symptoms. The proportion of
outpatient visits in which MHT was prescribed dropped from 83.0% (n = 1,155) before WHI to
73.0% (n = 844) after WHI. We found a decrease in likelihood that women would be prescribed
MHT for menopause-related symptoms after the release of the WHI report (OR = 0.36, 95%CI =
0.25 to 0.52, p < 0.05). Gynecologists and obstetricians are more likely to prescribe MHT than
physicians with other medical specialties (5.34; 95%CI = 3.45 to 8.26, p < 0.05). Women with
college level educations or higher became less likely to be prescribed MHT (Model 2; OR 0.30; 95%
CI 0.11–0.83), and academic medical centers became less likely to prescribe MHT than other
medical care institutions (Model 3; OR 0.15; 95% CI 0.34–0.63).
Conclusion: The WHI report caused a substantial decline in the use of MHT to treat menopause-
related symptoms in Taiwan. It was found to exert most of its influence in patients with higher
educations, physicians with specialties other than gynecologists and obstetricians, and academic
medical centers.
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Background
Menopausal hormone therapy (MHT), estrogen with or
without progestin, has been commonly used to treat
symptoms of menopause and prevent chronic conditions
such as cardiovascular disease and osteoporosis since the
late 1960s [1]. Evidence on the potential risks and benefits
of combined estrogen/progestin has slowly accumulated
and has suggested that the combination of the two acts
differently than estrogen alone [2-4]. Evidence from sec-
ondary prevention trials and observational studies has
also shown that using combined estrogen/progestin ther-
apy comes with an increased risk of coronary heart disease
[5,6].
In 2002, the Women's Health Initiative (WHI) report [7]
demonstrated that the risks outweighed the benefits for
women undergoing continuous estrogen and progestin
treatment [5]. The WHI report findings prompted the U.S.
Food and Drug Administration to require new warning
labels be placed on all estrogen products [8], and
prompted the U.S. Preventive Services Task Force to rec-
ommend that estrogen and progestin not be used rou-
tinely in the prevention of chronic post-menopausal
conditions [9]. Although WHI results may not apply to
other types of estrogen and progesterone therapies, differ-
ent dosages, and various methods of administration, the
results were, nevertheless, significant enough to lead to a
substantial decline in the use of MHT by many postmen-
opausal women [10-17].
Consequently, the WHI report affected drug approval pol-
icy. The FDA (U.S.) now only approves estrogen for the
relief of menopause symptoms alone regardless of formu-
lation, dosage, or route of administration. Furthermore, it
has been recommended that only women at a significant
risk of osteoporosis consider hormone therapy, at recom-
mended dosage decreased from 0.625 mg conjugated
estrogens to 0.3 mg [36]. Because the impact of the WHI
report may demonstrate that what some studies have
claimed- the dissemination and availability of health care
information influence consumer perception and demand
for medical care [10,18-20], we believe that a closer exam-
ination of the effect of WHI report on the use of MHT
treatment might lead to a better understanding of the role
of "information" in the demand and supply of medical
services.
Certain consumer characteristics including age, educa-
tional level, working status, and marital status, influence
whether or not a woman seeks and accepts MHT [1,15,21-
24]. Also, possession of information or knowledge,
largely obtained through medical and social contacts, has
a great influence on the acceptance of MHT [[15,23,25],
and [26]]. Furthermore, the opinion of a woman's health
care provider has also been found to strongly influence
her decision to undergo MHT [27].
Which medical interventions health care providers decide
to use depend on their access to technical information,
recommended procedures and regimen, and reported
"uncertainties" about the effectiveness of the intervention
[28]. Incomplete information, as being one of the main
reasons, is often cited that physicians vary in how they
treat a particular medical condition and in their patterns
of practice [29]. Preference of medical intervention can
also depend on medical specialty of the physician.
Women treated by gynecologists have been reported to be
2.6 times more likely to receive MHT than women being
treated by family physicians [30], which is understanda-
ble in light of the finding that gynecologists have a more
favorable attitude toward MHT as a preventive measure
than other physicians [31-33].
Forty to 60-year-old women in Taipei, Taiwan increased
their use of MHT from 8.8% to 19% between 1991 and
1997 [34]. Most of these women were encouraged to seek
this therapy by their social contacts, medical professionals
and the media. The government even had a television
advertisement promoting MHT in 1999. However, four
months after the release of WHI report, the government
formed an ad hoc committee that later announced new
guidelines for the use of MHT, though the television pro-
motion of MHT was withdrawn much earlier. [35].
With regard to WHI report's impact over physician and
patients, it is not clear whether it affected their willingness
to prescribe or use MHT in Taiwan. Using the results of a
national health interview survey administered between
August 2001 and January 2002 and linking them with the
National Health Insurance (NHI) outpatient claims for
women with menopausal conditions, we examined the
changes of prescription of MHT to treat menopausal out-
patients in Taiwan before and after the publication of
WHI report as well as to what extent certain patient or
health care provider characteristics influenced the deci-
sion to use MHT.
Methods
Data source
Data was drawn from two sources: the 2001 National
Health Interview Survey (NHIS) and the NHI outpatient
records of interviewees who consented to the linking of
their personal information from the two sources. The data
from the 2001 NHIS was collected between August 2001
and January 2002. The survey, using a stratified multistage
sampling design with the probability of selection propor-
tional to population size, included a representative sam-
ple of Taiwan's population of 23 million people and an
over sampling of residents in the mountain regions andBMC Public Health 2007, 7:56 http://www.biomedcentral.com/1471-2458/7/56
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Taiwan's various offshore islands. The primary sample
units, segmented based on their level urbanization levels
defined by their socioeconomic and demographic charac-
teristics, were 368 townships throughout Taiwan and out-
lying islands, 12 districts in the Taipei Municipality, and
11 districts in the Kaohsiung Municipality. All family
members of each sampled household were included in
our sample. NHI data were linked with NHIS data by per-
sonal identification number only if the respondents in the
survey signed the informed consent.
The survey included 23,473 individuals (5798 house-
holds), representing Taiwan's general population. From
this pool, we selected 3439 women 45 years old or above.
After excluding 564 women who did not consent to the
linkage of their survey data with their NHI data (21 with
missing data), we were left with 2875 participants. Those
who refused to participate were more likely to be older
(aged 65 years or above, p < 0.0005), lack formal educa-
tion (p < 0.0005), be unmarried (p < 0.05), be unem-
ployed (p < 0.0005), or lack personal income (p < 0.0005)
(Table 1).
We also reviewed the participant's January 1, 2002 to
December 31, 2002 NHI outpatient claims. Out of the
2875 female participants, 504 had NHI records indicating
they had sought treatment for menopause related prob-
lems during the study period starting six months before
and ending six months after the WHI report was pub-
lished.
Measures
In this study, the dependent variable was whether or not
MHT was prescribed during outpatient visits for meno-
pause-related symptoms. A menopause-related visit was
defined if the patient was diagnosed as having a meno-
pausal condition represented by one of the seven
ICD9CM codes: 627.0 menopausal menorrhagia, 627.1
postmenopausal bleeding, 627.2 menopausal or female
climacteric states, 627.3 postmenopausal atrophic vagin-
itis, 627.4 states associated with artificial menopause,
627.8 other specified menopausal & postmenopausal dis-
orders, or 627.9 unspecified menopausal & postmeno-
pausal disorder. We created a dummy variable to indicate
whether or not MHT was prescribed: 1, if estrogen was
prescribed; zero, if not.
Independent variables included the effect of WHI report,
variables related to outpatient visits for menopause and
variables of patient demographics. A dummy variable was
created to indicate whether the WHI report had been
released. A value of 1 was assigned if an outpatient visit
occurred on or after July, 2002 and a value of 0 if a visit
occurred during the first half of 2002. Variables related to
outpatient visits for menopause, including the categories
of health care institution and physician specialty, were
mainly extracted from NHI outpatient records. Health
care institutions were classified into four accreditation lev-
els: academic medical centers, metropolitan hospitals,
local community hospitals, and physician clinics. A
dummy variable was assigned to physician specialty, 1 if
the patient was treated by an obstetrician or a gynecolo-
gist, and 0 if treated by a physician of any other medical
specialty. Patient demographic data, including age, mari-
tal status, employment status, and monthly income, were
obtained from the 2001 NHIS. Patients were categorized
into the following three age groups: 45–54, 55–64, 65 and
above. Dummy variables were also created for marital sta-
tus, employment status: 1 indicating yes, and zero indicat-
ing no. Personal monthly income was divided into five
categories: no income, less than NT $5000, $5000 –
19999, $20000 – 39999 and NT $40,000 or above.
Two dummy health status variables were also created. The
first dummy health status variable, which represented
whether the respondent experienced illnesses during the
six-month period leading up to the interview, was
extracted from the 2001 NHIS. A value of 1 was assigned
if any kind of illness had been experienced, and a value of
0 if not. Another dummy health status variable, represent-
ing whether the patient had been diagnosed as having
osteoporosis, was extracted from the NHI outpatient
record. A value of 1 was assigned if the patient had been
diagnosed or treated for osteoporosis or osteoporosis-
related condition (ICD9CM = 733.00 osteoporosis,
unspecified, 733.01 senile osteoporosis, 733.02 Idio-
pathic osteoporosis, 733.03 disuse osteoporosis, 733.09
other osteoporosis), and a value of 0 if not.
Statistical analysis
Our unit of analysis was 2,549 outpatient visits for meno-
pause-related symptoms of 504 study participants. Our
reference group included women visiting outpatient visits
for menopause-related symptoms before the WHI report.
Logistic regressions were used to analyze the effect of the
WHI report and women's characteristics such as age, edu-
cational level, marital status, employment status, personal
monthly income, illness during the previous six months
and osteoporosis on the likelihood that MHT was pre-
scribed in the outpatient visit for menopause-related
symptoms. To reduce the effect of repeated measure-
ments, we estimated logistic regressions using random-
effect model. Data management and logistic regression
model used in our study was done using SAS Version 8.0
(Chicago, Illinois).
In addition, we introduced interaction terms of WHI with
these two variables in another two logistic regressions:
one with WHI interacting with medical institution charac-
teristics, and another one with WHI interacting withBMC Public Health 2007, 7:56 http://www.biomedcentral.com/1471-2458/7/56
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women's educational levels. The interaction models were
used to explore the association of the period (before and
after the release of WHI report) and the prescription of
MHT in different levels of education and accreditation lev-
els of medical facility. A linear function of the coefficient
was estimated and tested in these models with the interac-
tion terms. Other covariates were also included in these
models. However, in order to simplify interpretation, we
showed the effect of publication of the WHI on the four
types of hospitals instead of the interaction terms. Also,
we showed the effect of publication of the WHI on the five
levels education instead of the interaction terms.
Results
The NHI records of 504 participants indicated that they
had sought treatment for menopause related problems
during the study period starting six months before and
ending six months after the WHI report was published
(Table 2). Of these 504 women, 28.6% (n = 144) had NHI
outpatient records for menopause only during the six-
month period leading up the release of WHI report,
51.2% (n = 258) before and after, and 20.2% (n = 102)
during the 6-month period following the WHI period
only (Table 2). Of the 402 women who had outpatient
visits for menopause related problems both before the
WHI report, 361 (89.8%) of them had at least one outpa-
tient record with MHT prescription, 288 (80%) of 360
women, who had NHI outpatient visits for menopause six
months after the WHI report, had at least one outpatient
record with a MHT prescription.
Most of the 504 study participants, who had outpatient
visits for menopause during our study period, were aged
45 – 55 years old (57.9%), had elementary school educa-
Table 1: Characteristics of females aged 45 years or above, with and without informed consent.
Totala (n = 3439) No consent (n = 543) Consent (n = 2875) P-valueb
N%n % n %
Demographic factors
Age <0.0001
45–55 1,500 43.6 185 34.1 1,305 45.4
55–65 909 26.4 153 28.2 751 26.1
65+ 1,030 30.0 205 37.8 819 28.5
Education <0.0001
None 997 29.0 223 41.1 767 26.7
Elementary school or lower 1,446 42.1 201 37.0 1,239 43.1
Junior high school 333 9.7 40 7.4 291 10.1
Senior high school 418 12.2 57 10.5 358 12.5
Undergraduate or graduate 243 7.1 21 3.9 219 7.6
Missing 2 0.1 1 0.2 1 0.0
Marital status 0.0138
Unmarried 951 27.7 174 32.0 773 26.9
Married 2,488 72.4 369 68.00 2,102 73.1
Economic factors
Employment status 0.0001
Employed 1,046 30.4 117 21.6 919 31.9
Unemployed 2,389 69.5 424 78.1 1,956 68.0
Missing 4 0.1 2 0.4 0 0
Personal income (NT $) 0.0005
None 1,448 42.1 270 49.7 1,173 40.8
<4.999 494 14.4 83 15.3 409 14.2
5,000~9,999 269 7.8 34 6.3 234 8.1
10,000~14,999 269 7.8 42 7.7 223 7.8
15,000~19,999 261 7.6 33 6.1 227 7.9
20,000~39,999 418 12.2 46 8.5 367 12.8
>= 40,000 243 7.1 27 5.0 215 7.5
Missing 37 1.1 8 1.50 27 1.0
Health Status 0.1672
Illness in the past six months
No 757 22.0 107 19.7 643 22.4
Yes 2,680 78.9 436 80.3 2,230 77.6
Missing 2 0.1 0 0 2 0.1
a21 missing without consent choice; P-valueb: chi-square test BMC Public Health 2007, 7:56 http://www.biomedcentral.com/1471-2458/7/56
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tions or lower (48.6%), were married (81.8%), were not
employed (66.5%) or had no personal income (39.1%).
Of these 504 females, most (84.9%) had experienced an
illness during the six-month period leading up to the
interview, and most (70.0%) had no NHI outpatient
records for osteoporosis. In total, these 504 women made
2549 outpatient visits for menopause-related symptoms,
50.8% were being treated by either an obstetrician or
gynecologist and 79.3% had been prescribed MHT. The
proportion of outpatient visits in which MHT was pre-
scribed dropped from 83.0% (n = 1392) before WHI to
73.0% (n = 1157) after WHI.
Table 3 shows the results of logistic regressions of random
effect. Model 1 included the dummy variable of WHI
effect without interaction terms; Model 2 included the
interaction of WHI and women education; and Model 3
included the interaction of WHI and the accreditation
level of medical institution. Overall, based on Model 1,
the likelihood that MHT would be prescribed during an
outpatient visit decreased after the WHI report (OR 0.36,
95%CI 0.25 to 0.52). Hospitals not classified as academic
medical centers were more likely to prescribe MHT than
academic medical centers (OR from 14.87 for metropoli-
tan hospital to 26.42 for physician clinic). Obstetricians
or gynecologists were more likely to prescribe MHT than
physicians of other specialties (OR 5.34, 95% CI 3.45–
8.26). Marital status, employment status, personal
income, the diagnosis of osteoporosis, or illness was not
found to be associated with the prescription of MHT the
six months leading up to the interview. The impact of the
WHI report on the prescription of HRT analyzed by level
of education and the accreditation level of medical care
institution was estimated in the two interaction models,
Model 2 and Model 3. Women with college level educa-
tions or higher were less likely to be prescribed MHT after
the WHI report than before (Model 2; OR 0.30; 95% CI
0.11–0.83). Academic medical centers were less likely to
prescribe MHT than other medical care institutions after
the release of WHI report (Model 3; OR 0.15; 95% CI
0.34–0.63).
Discussion
MHT was once widely thought to be an effective treatment
for menopause-related symptoms. In year 2002, the WHI
trial of estrogen plus progestin in postmenopausal
women found that overall health risks of this therapy out-
weighed the benefits for these women [7]. The release of
that report provides us the opportunity to study to what
extent publicizing new scientific evidence changes public
acceptance of certain modes of therapy and health care
provider's choice of therapeutic regimens, in this case
menopausal hormone therapy.
In this study, as other studies have indicated, the WHI
report led to a significant decline on the use of MHT for
menopausal difficulties [12-16]. Like other studies [29-
32], we found that gynecologists were more likely to pre-
scribe MHT than physicians with other medical special-
ties, but we also found that the decision whether MHT
would be prescribed was not totally decided by physicians
alone, but had also to do with who was seeking therapy.
Women with college level educations or higher were less
likely to be prescribed MHT than the women with high-
school level educations or lower and health care providers
were found to vary considerably in whether MHT was pre-
scribed.
One of the limitations of this study is its focus on the MHT
for the treatment of menopausal-related symptoms. We
did not take into account that some women might stop
seeking western medicine treatment at outpatient visits
for menopausal-related symptoms and start searching for
other non-pharmacological treatments (e.g. herbal prod-
ucts or health supplements). Since our data source was
obtained from the NHI outpatient visit records, no infor-
mation on over-the counter herbal products or nutritional
supplements for menopausal symptoms was included.
Thus, our findings may underestimate women's reaction
to the WHI report. Nevertheless, our sample was drawn
from a nationwide interview survey and linked to NHI
claim data, allowing us to obtain real utilization informa-
tion and identify the co-existing condition of osteoporo-
sis. Data collected this way is superior to self-reported
information, which can be subject to recall bias. 98.3% of
the people we surveyed were insured under the NHI pro-
gram, with almost all of their medical costs covered
through this program. This lends credence to our findings,
in that financial barriers to MHT were non-existent.
Another limitation of our study is potential selection bias.
The sample base for this study was drawn from the
women who were interviewed in the 2001 National
Health Interview Survey and aged 45 years or above. Only
those who signed the inform consent for linking NHI
claim data would be included in this study. Those who
did not sign the inform consent were more likely to be
older, less educated, unmarried, unemployed, have lower
personal income and be healthier. Our logistic regression
predicted that women who were unemployed and less
educated women were more likely to be prescribed MHT.
Thus, we would suspect that those women who were not
included in this paper were those who were more likely to
be prescribed MHT. After the WHI report, women with
undergraduate or graduate (higher education) were less
likely to receive MHT OR = 0.30 (0.11–0.83). Again, we
suspect that the effect of WHI on reducing prescription of
MHT may be somewhat over-estimated, because lower-BMC Public Health 2007, 7:56 http://www.biomedcentral.com/1471-2458/7/56
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educated women were more likely to be excluded and less
responsive to WHI report than higher-educated women.
Finally, this study was undertaken only six months fol-
lowing publication of the WHI report. In order to keep
track of stable changes in the patterns of practice patterns
that take place after publication of such an article, longer
follow-up periods may be necessary, especially of sub-
groups of women such as women with previous hysterec-
tomies, those older than 65, and women living in areas of
high social deprivation. Future research should consider
factors leading to the effective dissemination of new clin-
ical trial findings for women.
Conclusion
The WHI report brought about a substantial decline in the
prescription of MHT to treat menopause-related symp-
toms in Taiwan. The decision whether to prescribe MHT
for menopause-related symptoms was not purely domi-
nated by the physician. Women with college level educa-
Table 2: 504 females aged 45 years or above with outpatient visits for menopause
Number of individuals having outpatient visits for menopause (N = 504)
Total (N = 504) Before WHI (N = 402) After WHI (N = 360)
N% N % N %
Demographic factors
Age
45–55 292 57.9 232 57.7 214 59.4
55–65 142 28.2 111 27.6 103 28.6
65+ 70 13.9 59 14.7 43 11.9
Education
None 70 13.9 53 13.2 48 13.3
Elementary school or lower 245 48.6 194 48.3 170 47.2
Junior high school 63 12.5 56 13.9 48 13.3
Senior high school 83 16.5 63 15.7 61 16.9
Undergraduate or graduate 43 8.5 36 9.0 33 9.2
Missing 0
Marital status
Unmarried 92 18.3 76 18.9 60 16.7
Married 412 81.8 326 81.1 300 83.3
Economic factors
Employment status
Employed 169 33.5 133 33.1 120 33.3
Unemployed 335 66.5 269 66.9 240 66.7
Personal income (NT $)
None 197 39.1 157 39.1 139 38.6
<4,999 56 11.1 44 11.0 38 10.6
5,000~19,999 104 20.6 86 21.4 79 21.9
20,000~39,999 87 17.3 64 15.9 64 17.8
>= 40,000 55 10.9 47 11.7 36 10.0
Missing 5 1.0 4 1.0 4 1.1
Health Status
Illness in the past six months
No 76 15.1 65 16.2 48 13.3
Yes 428 84.9 337 83.8 312 86.7
Osteoporosis
No 353 70.0 294 73.1 274 76.1
Yes 151 30.0 108 26.9 314 23.9
#Total outpatient visits for 2549 1392 1157
menopause-related symptoms
Proportion of visits prescribing 1999 78.4 1155 83.0 844 73.0
MHT
Proportion of visits prescribing
MHT (stratified by type of institution)
Academic medical center 475 58.7 278 65.2 196 49.0
Metropolitan hospital 627 82.9 342 84.8 285 80.7
Local community hospital 492 81.1 244 87.7 248 74.6
Physician clinic 955 83.9 527 89.0 428 77.6
Proportion of visits served by obstetricians or gynecologists 1295 50.8 712 51.2 583 50.4
#: Of these 504 women, 28.6% (n = 144) had NHI outpatient records for menopause only during the six-month period leading up the release of 
WHI report, 51.2% (n = 258) before and after, and 20.2% (n = 102) during the 6-month period following the WHI period onlyBMC Public Health 2007, 7:56 http://www.biomedcentral.com/1471-2458/7/56
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Table 3: Logistic regressions of random effect for MHT treatment in menopause outpatient visits
Outpatient visits (% prescribing MHT) Model 1 – no 
interaction
Model 2 – interaction 
of WHI and woman 
education
Model 3 – interaction 
of WHI and hospital 
level
n% a Odds Ratio (95% CI) Odds Ratio (95% CI) Odds Ratio (95% CI)
WHI report announcement
After 1157 72.95 0.36 (0.25–0.52)
Before (reference group) 1392 82.97
Medical care institution
Metropolitan hospital 627 82.93 14.87 (7.28–30.37) 11.98 (5.82–24.68) 7.02 (3.23–15.27)
Local community hospital 492 81.10 17.00 (7.92–36.49) 12.09 (5.81–25.14) 12.13 (4.84–30.41)
Physician clinic 955 83.87 26.42 (13.34–52.32) 16.52 (8.43–32.39) 18.22 (8.12–40.89)
Ref: Academic medical center 475 58.74
WHI on Medical care institutionb
WHI effect on metropolitan 
hospital
6.25 (2.08–18.72)
WHI effect on local community 
hospital
1.69 (0.52–5.49)
WHI effect on physician clinic 2.13 (0.76–5.98)




Obstetrician or gynecologist 1295 85.10 5.34 (3.45–8.26) 6.26 (3.92–10.00) 5.56 (3.60–8.58)
Ref: other specialty 1254 71.53
Demographic factors
Age 0.73 (0.41–1.32) 0.72 (0.37–1.40) 0.66 (0.36–1.20)
55–65 719 75.52
65+ 348 83.62 2.33 (0.81–6.69) 2.43 (0.86–6.92) 4.38 (1.41–13.54)
Ref: 45–55+ 1482 78.61
Education
Senior high school 373 75.87 0.53 (0.21–1.35) 0.33 (0.09–1.21) 2.46 (1.02–5.93)
Junior high school 446 78.03 0.54 (0.19–1.55) 0.38 (0.11–1.31) 3.11 (1.19–8.10)
Elementary school or lower 1180 80.76 0.95 (0.41–2.19) 0.62 (0.22–1.80) 4.50 (1.83–11.04)
No 322 79.19 1.18 (0.43–3.20) 1.10 (0.31–3.84) 4.90 (1.75–13.72)BMC Public Health 2007, 7:56 http://www.biomedcentral.com/1471-2458/7/56
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Ref: Undergraduate or 
graduate
228 70.18
WHI effect on woman educationc
WHI effect on women with senior 
high school
1.64 (0.43–6.22)
WHI effect on women with junior 
high school
1.10 (0.29–4.16)
WHI effect on women with 
elementary school or lower
1.28 (0.40–4.08)
WHI effect on women with no 
education
0.85 (0.20–3.53)




Married 2141 77.11 1.03 (0.51–2.10) 0.64 (0.34–1.22) 1.18 (0.62–2.23)
Ref: Unmarried 408 85.29
Economic factors
Employment status
Employed 841 79.31 0.94 (0.45–1.94) 0.37 (0.17–0.76)* 0.63 (0.30–1.30)
Ref: Unemployed 1708 77.99
Personal income (NT $)
<4,999 293 78.16 0.73 (0.31–1.72) 0.66 (0.28–1.59) 0.76 (0.31–1.89)
5,000~19,999 562 79.89 0.72 (0.30–1.71) 0.36 (0.28–1.59) 0.74 (0.32–1.73)
20,000~39,999 431 79.35 1.20 (0.57–2.55) 0.39 (0.18–0.85) 1.14 (0.53–2.45)
>= 40,000 259 71.43 0.24 (0.09–0.59) 0.33 (0.13–0.85) 0.86 (0.31–2.39)
Ref: None 993 79.15
Health Status
Illness in the past six months
Yes 2188 78.11 1.08 (0.49–2.39) 2.18 (1.07–4.47) 0.81 (0.38–1.73)
Ref: No 361 80.33
Osteoporosis
Yes 741 80.43 1.63 (0.91–2.89) 1.48 (0.84–2.59) 1.37 (0.80–2.33)
Ref: No 1808 77.60
%a: Percentages in the second column of table 3 were the proportion of outpatient visits with a prescription of MHT in each category. For example, among the 1,157 
outpatient visits after the publication of WHI report, there're 72.95% (844 visits) with a prescription of MHT.
WHI and Medical care institutionb: A linear function of the coefficient was estimated and tested in Model 3 with the interaction terms. In order to simplify interpretation, we 
showed the effect of publication of the WHI on the four types of hospital instead of the interaction terms.
WHI effect and woman educationc: A linear function of the coefficient was estimated and tested in Model 2 with the interaction terms. In order to simplify interpretation, we 
showed the effect of publication of the WHI on the five categories of level of women education instead of the interaction terms.
Table 3: Logistic regressions of random effect for MHT treatment in menopause outpatient visits (Continued)BMC Public Health 2007, 7:56 http://www.biomedcentral.com/1471-2458/7/56
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tions or higher were less likely to be prescribed MHT than
the women with high-school level education or lower
after the release of WHI report, and academic medical
centers were less likely and metropolitan hospitals more
likely to prescribe MHT than medical providers with dif-
ferent accreditations after the release of WHI report.
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